Cite this article
Can We Cure Atherosclerosis?
1 Departments of Epidemiology & Medicine, University of Iowa College of Public Health and Carver College of Medicine, Iowa City, IA
2 Department of Cardiology, University of Chicago Medicine, Chicago, IL
Rev. Cardiovasc. Med. 2018 , 19(S1), 20–24; https://doi.org/10.3909/ricm19S1S0003
Published: 20 January 2018
Cardiovascular disease mortality rates have begun to rise in the United States. Based on the large body of supportive evidence, we propose a proof-of-concept, first-in-human trial to cure atherosclerosis: CURing Early ATHEROsclerosis (CURE ATHERO). This trial is based on a model of intensive induction therapy for extensive, if not complete, plaque regression, followed by intermittent maintenance therapy. An extensive body of evidence has demonstrated the causal role of apolipoprotein B lipoproteins in atherosclerosis progression and data suggest intensive low-density lipoprotein cholesterol (LDL-C) lowering may have a substantial impact on earlier stages of atherosclerosis. Compared with lifetime treatment to prevent atherosclerosis progression, this induction–intermittent treatment model will minimize costs and maximize adherence and safety.
Apolipoprotein B lipoproteins
PCSK9 monoclonal antibodies